Muko, Japan

Yuji Iizawa



 

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 46(Granted Patents)


Location History:

  • Osaka, JP (2007)
  • Muko, JP (2002 - 2013)
  • Kyoto, JP (2008 - 2018)

Company Filing History:


Years Active: 2002-2018

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovations of Yuji Iizawa

Introduction

Yuji Iizawa is a notable inventor based in Muko, Japan. He has made significant contributions to the field of cyclic compounds, particularly in the area of CCR antagonists. With a total of nine patents to his name, Iizawa's work has implications in various therapeutic applications.

Latest Patents

One of Yuji Iizawa's latest patents is focused on a bicyclic compound that exhibits CCR antagonist activity, specifically targeting CCR5. This invention provides a new cyclic compound represented by a specific formula, which includes a 5- to 6-membered ring group that may be substituted, a bivalent group of 1 to 4 atoms, and an amino group or nitrogen-containing heterocyclic group. The compound's potential use in medical applications highlights its importance in the field of pharmacology.

Career Highlights

Throughout his career, Yuji Iizawa has worked with prominent companies such as Tobira Therapeutics, Inc. and Takeda Chemical Industries, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical industry.

Collaborations

Yuji Iizawa has collaborated with notable colleagues, including Mitsuru Shiraishi and Masanori Baba. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Yuji Iizawa's contributions to the field of cyclic compounds and CCR antagonists demonstrate his innovative spirit and dedication to advancing medical science. His work continues to influence the pharmaceutical industry and offers promising avenues for future research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…